The
neuroprotective effects of a systemically active, highly selective,
corticotropin-releasing factor-1 (
CRF1) receptor antagonist,
R121920 ((7-(dipropylamino)-2,5-dimethyl-3- [2-(dimethylamino)-5-pyridyl] pyrazolo [1,5-a]
pyrimidine), was assessed in two rat models of permanent focal
cerebral ischemia, where the middle cerebral artery (MCA) was occluded either through the subtemporal approach or using the intraluminal
suture technique.
R121920 rapidly crossed the blood-brain barrier after intravenous (IV) bolus administration (10 mg/kg), with peak brain concentrations at 5 minutes (2.26 +/- 0.40 microg/mL), which were approximately 2-fold greater than those in plasma (0.98 +/- 0.24 microg/mL). Treatment with
R121920 (10 mg/kg IV followed by 5 mg/kg subcutaneously at hourly intervals for 4 hours) significantly (P < 0.001) reduced total (by 40%) and cortical (by 37%)
infarct volume at 24 hours after subtemporal MCA occlusion (MCAO). In the intraluminal
suture MCAO model, IV administration of
R121920 (10 mg/kg) at the time of
ischemia onset (and at multiple times thereafter) reduced both hemispheric
infarct volume (by 34%, P < 0.001) and
brain swelling (by 50%, P < 0.001) when assessed at 24 hours. In this model of focal
ischemia, significant reduction (P < 0.05) in both outcome measures was obtained when
R121920 administration was delayed up to 1 hour after MCAO. These results further define the antiischemic properties of selective CRF 1 antagonists in two experimental models of permanent focal
cerebral ischemia.